Drug repurposing is a fast and consolidated approach for the research of new active compounds bypassing the long streamline of the drug discovery process. Several drugs in clinical practice have been reported for modulating the major Hippo pathway’s terminal effectors, namely YAP (Yes1-associated protein), TAZ (transcriptional co-activator with PDZ-binding motif) and TEAD (transcriptional enhanced associate domains), which are directly involved in the regulation of cell growth and tissue homeostasis. Since this pathway is known to have many cross-talking phenomena with cell signaling pathways, many efforts have been made to understand its importance in oncology. Moreover, this could be relevant to obtain new molecular tools and potential therapeutic assets. In this review, we discuss the main mechanisms of action of the best-known compounds, clinically approved or investigational drugs, able to cross-talk and modulate the Hippo pathway, as an attractive strategy for the discovery of new potential lead compounds.

Repurposing of drugs targeting yap-tead functions / Elisi, GIAN MARCO; Santucci, M.; D'Arca, D.; Lauriola, A.; Marverti, G.; Losi, L.; Scalvini, L.; Bolognesi, M. L.; Mor, M.; Costi, M. P.. - In: CANCERS. - ISSN 2072-6694. - 10:9(2018), p. 329. [10.3390/cancers10090329]

Repurposing of drugs targeting yap-tead functions

ELISI, GIAN MARCO;Scalvini L.;Mor M.;
2018-01-01

Abstract

Drug repurposing is a fast and consolidated approach for the research of new active compounds bypassing the long streamline of the drug discovery process. Several drugs in clinical practice have been reported for modulating the major Hippo pathway’s terminal effectors, namely YAP (Yes1-associated protein), TAZ (transcriptional co-activator with PDZ-binding motif) and TEAD (transcriptional enhanced associate domains), which are directly involved in the regulation of cell growth and tissue homeostasis. Since this pathway is known to have many cross-talking phenomena with cell signaling pathways, many efforts have been made to understand its importance in oncology. Moreover, this could be relevant to obtain new molecular tools and potential therapeutic assets. In this review, we discuss the main mechanisms of action of the best-known compounds, clinically approved or investigational drugs, able to cross-talk and modulate the Hippo pathway, as an attractive strategy for the discovery of new potential lead compounds.
2018
Repurposing of drugs targeting yap-tead functions / Elisi, GIAN MARCO; Santucci, M.; D'Arca, D.; Lauriola, A.; Marverti, G.; Losi, L.; Scalvini, L.; Bolognesi, M. L.; Mor, M.; Costi, M. P.. - In: CANCERS. - ISSN 2072-6694. - 10:9(2018), p. 329. [10.3390/cancers10090329]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2861604
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 36
social impact